Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 21;12:925411. doi: 10.3389/fonc.2022.925411

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Chu, Hong and Zheng

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Clinical validation of FDX1. (A) Differential expression of FDX1 in TCGA pan-cancer. (B) A meta-analysis of the prognosis of pan-cancer with FDX1. (C) Differential expression of FDX1 in normal and tumor tissues in the Taizhou cohort. (D) Overall survival differences between high and low FDX1 expression groups in the Taizhou cohort. (E) Table of clinicopathological characteristics of the Taizhou cohort. Differences in clinicopathological characteristics, including Age (F), and Gender (G), T stage (H), N stage (I), and M stage (J), Grade (K), between high and low FDX1 expression groups in the Taizhou cohort. (L) HE staining of tumors and adjacent normal renal tissues in Taizhou cohort. (M) Immunohistochemical detection of FDX1 in tumors and adjacent normal renal tissues in Taizhou cohort. ^*P< 0.05, ^**P< 0.01, ^***P< 0.001.